Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT

Exclusion Criteria

• •1. Patients who didn't achieved complete remission before transplantation (bone marrow smear: proportion of primordial cells \>=5%) or any extramedullary recurrence.
• •2. Patients who were previously known to be resistant to venetoclax.
• •3. In patients with severe pulmonary insufficiency (obstructive and / or restrictive ventilation disorders), the researchers evaluated the patients who could not tolerate the super pretreatment scheme.
• •4. Patients with severe liver function impairment and liver function indexes (alt, TBIL) more than 3 ULN were evaluated as intolerant of super pretreatment.
• •5. In patients with severe renal insufficiency, the renal function index (CR) is more than 2 times of the upper limit of the normal value (ULN), or the 24-hour creatinine clearance rate (CR) is less than 50ml / min, the researchers evaluated that they could not tolerate the super pretreatment scheme.
• •6. In patients with severe active infection, the researchers evaluated that they could not tolerate the pretreatment.
• •7. Patients who had allergic reactions or serious adverse reactions in the previous use of pretreatment related drugs could not be included in the study.
• •8. Other reasons why the researchers could not be selected.